Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Wihlborgs signs lease with the Swedish Defence Recruitment Agency

Wihlborgs has signed a lease with the Swedish Defence Recruitment Agency, which is opening a department for selection tests in Malmö. The Agency is moving into premises of 2,500 m² at Norra Vallgatan 100 in central Malmö.The premises will be redesigned to meet the needs of the Agency’s selection testing activities, which will conduct a variety of tests on several hundred applicants each week. On 1 December this year, the premises will be ready for occupation and the Agency will start operations in January 2018. The Swedish Defence Recruitment Agency is tasked with calling up, evaluating

Etteplan steps it up in China

An industrial shift and a new need for outsourcing expert services have opened up plenty of new growth opportunities for Etteplan in China: the engineering company is strengthening its foothold and simultaneously advancing its growth by opening two new offices in the country. The company has been active in China since 2004.The new cyclical nature of China’s market and the rise in labor costs in all pay classes has led China on a quest for cost-efficiency and flexibility. This has caused not only the purchasing of expert services to become more popular but also the modernization of

New record date for the distribution of free warrants.

The record date for the warrants issued by Brighter to its shareholders in order to minimize dilution from the financing solution announced by the company on April 26, is postponed until May 15 due to technical reasons. For more information, please contact:Truls Sjöstedt, CEO         Tel: +46 709 73 46 00         Email: truls.sjostedt@brighter.se  Henrik Norström, COO         Tel: +46 733 40 30 45         Email: henrik.norstrom@brighter.se About Brighter AB (publ) Brighter develops healthtech solutions with its data-driven mobile health services. Through its

Autoliv announces changes to Board of Directors

(Stockholm, Sweden, May 8, 2017) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, announced that Ms. Aicha Evans, a member of the Board of Directors, will not stand for re-election to the Board.On May 6, 2017, Ms. Aicha Evans informed the Board of Directors of the Company that she has decided to not seek re-election to the Board at Autoliv’s 2017 annual general meeting of stockholders (“Annual Meeting”), to be held on May 9, 2017.  Ms. Evans determined that she will not continue her service on the Board due to changes in her current

Scandi Standard – First quarter presentation

Scandi Standard will publish its report for the first quarter on Thursday, 11 May 2017 at 07.30 CET. Conference call at 10.oo CET The Company will host a conference call for the financial community at 10.00 CET the same day. The conference call will be hosted by Leif Bergvall Hansen, CEO and Anders Hägg, CFO. Dial In numbers: Sweden 0200 125 877United Kingdom 020 3059 8125All other locations + 44 20 3059 8125 The presentation used in the conference call will be published at http://www.scandistandard.com prior to the call. The conference call will also be audio webcasted

Nomination proposal strengthens Idogen’s Board within cell therapy and drug development

Prior to the Idogen AB (publ) Annual General Meeting of 17 May 2017, the Nomination Committee has presented its proposal for a new Board. Chairman of the Board Agneta Edberg is proposed to be re-elected and re-election is also proposed for Board members Leif G. Salford and Ulf Blom. The Board members Cecilia Hollerup and Mikael Ørum have declined re-election and new Board members, Christina Herder and Karin Hoogendoorn, are proposed.The Nomination committee, representing Idogen’s largest shareholders, proposes that the Board of Directors consist of five ordinary members without alternates

Håkon Wibstad går til Beringer Finance som CFO/COO

Håkon Wibstad går til Beringer Finance fra Swedbank, hvor han har håndtert innfasingen av MiFID II regulativet i Swedbank Norge og ledet et kundedokumentasjon og hvitvaskings prosjekt. Han har også jobbet som Client Executive i Swedbank Wealth Management. Håkon starter i Beringer Finance 1 august og vil bli del av både toppledelsen og den norske ledelsen i Beringer Finance.“Vi setter full fokus på vår kjernevirksomhet; å bruke vår kunnskap og erfaring i å koble kundene som trenger kapital eller kapitaliserings og strategiske råd, med de som har kapital eller strategiske mål. Ved å ansette

Q1-2017 report Axactor AB

Enclosed is the consolidated Q1-2017 Financial Report for Axactor AB. Axactor AB had a revenue of EUR 19.7 million for first quarter 2017. This represents a 615% growth compared to same quarter last year. EBITDA is positive for the first time with EUR 1.0 million and cash EBITDA is positive with EUR 3.9 million. ERC at the end of the quarter was EUR 427 million which represents a growth compared to Q4-2016 of 36%.   For additional information, please contact:   Geir Johansen, CFO & Investor Relations, Axactor Mobile phone: +4747710451 Email: geir.johansen@axactor.

Implementation of Insplorion sensor in AGM batteries successful

Insplorion initiated a collaboration with AGM Batteries funded by an American power component company in September last year. The objectives were to develop battery cells with commercial manufacturing methods with integrated Insplorion sensors. The tests focusing on manufacturing methods, evaluation of fibre type and size as well as battery performance has proven successful.Over 20 cells with different fibres, sizes, positioning and mounting methodologies has been manufactured during the project. Extensive tests have been carried out on sealing integrity to ensure that the lithium-ion pouch

Interim Report  January – March 2017

· Sales increased by 6 percent to 3,775 MSEK (3,557) for the first quarter. In local currencies, sales increased by 3 percent. · Operating profit from product areas1) increased by 6 percent to 994 MSEK (939) for the first quarter. In local currencies, operating profit from product areas1) increased by 1 percent. · Operating profit2) amounted to 1,232 MSEK (1,711) for the first quarter, and included larger one-time items of 238 MSEK relating to the capital gains from divestment of shares in Scandinavian Tobacco Group (STG) and sale of land. The prior year included larger one-time items

Axactor increases existing loan facilities

Oslo 8 May 2017 - On May 5,  2017 the 4th tranche under the Recurring Credit Facility which Axactor has with DNB Bank ASA and Nordea Bank AS was made available to the company. Simultaneously the tranche was increased to EUR 45 million thereby increasing the available amount under the facility from EUR 100 million to EUR 120 million.  Furthermore NPL credit lines from regional banks in Italy have been increased to a total of EUR 55 million, and increase of EUR 25 million since the acquisition of CS Union. For additional information, please contact:   Geir Johansen,

Interim report January – March 2017

First quarter in brief · Net sales rose by about 26 percent to SEK 4,794k (3,808k). · Gross profit totaled SEK 4,128k (8,776k). · Gross margin was 89 (91) percent. · Operating loss improved to a loss of SEK 2,863k (loss: 3,449k). · Comprehensive income for the period improved by SEK 582k to a loss of SEK 2,872k (loss: 3,454k). · Comprehensive income per share, basic and diluted, improved by SEK 0.04 to SEK -0.05 (-0.09). · Cash flow from operating activities was SEK -1,586k (-2,498k).Comments from Fredrik Olsson, Chief Executive Officer   Increasing

Press invitation: Price lecture with Hernando de Soto

Magdalena Andersson, Minister for Finance, will act as presenter of the Global Award for Entrepreneurship Research 2017. The award goes to Hernando de Soto, President of the Institute for Liberty and Democracy (ILD) in Lima, Peru. Magdalena Andersson and Hernando de Soto will both be part of a panel discussion following the prize lecture.De Soto is one of our most influential thinkers in entrepreneurship and economics. In 1999 The Time magazine chose him as one of the five leading Latin American innovators of the 20th century. Then, President Bill Clinton called de Soto, in his opening

Proposals from the Nomination Committee to the Annual General Meeting in Cxense ASA

The full proposal is enclosed with this notice. Remuneration to the Board members: The annual Board remuneration is NOK 225,000 per Board member for the period from the date of the 2016 Annual General Meeting until the date of the 2017 Annual General Meeting. The Chairman of the Board receives an additional amount of NOK 75,000, and the members of the Audit Committee will receive an additional amount of NOK 25,000. In addition, the Company will refund relevant expenses that the members of the Board may have incurred in connection with the exercise of board functions. Election of

Invitation to presentation of Humana’s first quarter report 2017

Humana’s interim report for the first quarter 2017 will be published at 08:00 CET on May 18, 2017. A web-cast telephone conference will be held at 09:00 CET the same day, where CEO and President Rasmus Nerman and CFO Ulf Bonnevier will present the results for the first quarter 2017.A possibility will be given to ask questions via the webcast and follow the presentation material live. The webcast, which afterwards also will be available on demand, will be accessible at Humana’s financial website, http://corporate.humana.se. The presentation and webcast is also available on www.

Sales development in April 2017

H&M group sales including VAT increased by 7 percent in local currencies in April 2017 compared to the same month the previous year. The total number of stores in the group amounted to 4,474 on 30 April 2017 compared to 4,035 stores on 30 April 2016. Percentage sales development for the month of May and total revenue in SEK for the second quarter (March to May) will be published in a separate press release on 15 June 2017 at 08.00 (CET). The six-month report, covering the period 1 December 2016 to 31 May 2017, will be published on 29 June 2017 at 08.00 (CET). Karl-Johan Persson, CEO

VIGMED’S BOARD OF DIRECTORS HAS RESOLVED ON A DIRECTED NEW ISSUE OF SHARES PURSUANT TO AN AUTHORISATION GRANTED BY THE ANNUAL GENERAL MEETING

The Board of Directors of Vigmed Holding AB (publ) (“Vigmed” or the “Company”) has, pursuant to the authorisation granted by the annual general meeting on 12 May 2016, resolved on a directed new issue of 7,305,555 shares, which will raise proceeds to the Company of approximately SEK 8 million before deduction of issue costs.The board of directors has, pursuant to the authorisation granted by the annual general meeting on 12 May 2016, resolved on a directed new issue of 7,305,555 shares to its main shareholder, Greiner Bio-One GmbH (“GBO”).   The shares are issued at a subscription price

Inhalation Sciences AB raises 3.5 MSEK in new share issue ahead of IPO

STOCKHOLM, SWEDEN – May 8, 2017. Inhalation Sciences, a leading labtech company, has raised 3.5 MSEK in a private placement directed at current owners and a consortium of private Investors. The funds will be used to increase sales and development initiatives, moving the company towards its planned listing in Q.3 2017. Read the PDF here: Inhalation Sciences AB raises 3.5 MSEK in new share issue ahead of IPO  The new share issue raised a strong interest and was significantly

Ratos: Interim report January-March 2017

Press release 8 May 2107 This information is information that Ratos AB is obliged to make public pursuant to the EU Market Abuse Regulation.The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 8 May 2017. Development in company portfolio · Sales growth of 7% · Increase in EBITA from SEK 14m to SEK 102m · Increase of adjusted EBITA from SEK 95m to SEK 110m, +16% Acquisitions and divestments · Divestment of the remaining shareholding in Arcus, exit gain SEK 33m. Total exit gain amounted to SEK 1,

Clinical data on Elekta Unity from Elekta’s MR-linac Consortium featured in 20 abstracts at ESTRO 36

Advances in magnetic resonance radiation therapy (MR/RT) has the potential to transform accuracy, efficiency and clinical outcomes in radiation therapyVIENNA, May 8, 2017 – Elekta (EKTA-B.ST) today announced that Elekta Unity, the first magnetic resonance radiation therapy (MR/RT) system capable of delivering precisely targeted radiation doses while simultaneously capturing the highest quality magnetic resonance (MR) images, was featured in 20 abstracts at 36th ESTRO (European Society for Radiotherapy & Oncology) meeting. Elekta Unity, a transformative radiation delivery system integrates

CORRECTION: Kværner ASA: 1st quarter 2017 - Steady performance, solid order intake

This is a correction of the announcement from 06:58 08.05.2017 CEST. Reason for the correction: Financial appendix added as attachement to the release. 8 May 2017 - Kvaerner maintained steady performance and delivered a solid order intake in the first quarter of 2017. The company delivered an adjusted EBITDA of NOK 105 million, versus NOK 106 million in the same quarter last year.  In spite of the challenging market, the order intake in first quarter amounted to NOK 6.6 billion. With that, the order backlog has increased to NOK 10.8 billion. "We have a predictable performance in all

Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017

Oslo, Norway, 8 May 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will be hosting Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017. The meetings, which will be open to analysts, brokers, investors and press, will include presentations from world leading experts on resected pancreatic cancer patients, as well as from Targovax's senior management team. Presentations are expected to cover the following areas: · Introduction to Targovax

There are no items matching the current filter
There are no more items matching the current filter
Back to top